Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection.

Yee KL, Kleijn HJ, Kerbusch T, Matthews RP, Dorr MB, Garey KW, Wrishko RE.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01971-18. doi: 10.1128/AAC.01971-18. Print 2019 Feb.

PMID:
30455246
2.

Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.

Chris Min K, Dockendorf MF, Palcza J, Tseng J, Ma L, Stone JA, Kleijn HJ, Hodsman P, Masuo K, Tanen M, Troyer MD, van Vugt M, Forman MS.

Clin Pharmacol Ther. 2018 Oct 22. doi: 10.1002/cpt.1258. [Epub ahead of print]

PMID:
30347431
3.

Extending a Systems Model of the APP Pathway: Separation of β- and γ-Secretase Sequential Cleavage Steps of APP.

van Maanen EMT, van Steeg TJ, Ahsman MJ, Michener MS, Savage MJ, Kennedy ME, Kleijn HJ, Stone J, Danhof M.

J Pharmacol Exp Ther. 2018 Jun;365(3):507-518. doi: 10.1124/jpet.117.244699. Epub 2018 Mar 21.

PMID:
29563326
4.

Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling.

Li CC, Dockendorf M, Kowalski K, Yang B, Xu Y, Xie I, Kleijn HJ, Bosch R, Jones C, Thornton B, Marcantonio EE, Voss T, Bateman KP, Kothare PA.

J Clin Pharmacol. 2017 Nov 14. doi: 10.1002/jcph.1021. [Epub ahead of print]

PMID:
29136283
5.

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn HJ, Kuvelkar R, Li W, Mattson BA, Mei H, Palcza J, Scott JD, Tanen M, Troyer MD, Tseng JL, Stone JA, Parker EM, Forman MS.

Sci Transl Med. 2016 Nov 2;8(363):363ra150.

PMID:
27807285
6.

Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool.

van Maanen EM, van Steeg TJ, Michener MS, Savage MJ, Kennedy ME, Kleijn HJ, Stone JA, Danhof M.

J Pharmacol Exp Ther. 2016 Apr;357(1):205-16. doi: 10.1124/jpet.115.230565. Epub 2016 Jan 29.

PMID:
26826190
7.

A PK-PD model-based assessment of sugammadex effects on coagulation parameters.

Bosch R, van Lierop MJ, de Kam PJ, Kruithof AC, Burggraaf J, de Greef R, Visser SA, Johnson-Levonas AO, Kleijn HJ.

Eur J Pharm Sci. 2016 Mar 10;84:9-17. doi: 10.1016/j.ejps.2015.12.028. Epub 2015 Dec 30.

PMID:
26747019
8.

Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.

Liem-Moolenaar M, Peeters P, Kamerling IM, Hogg C, Holder G, Kleijn HJ, Spaans E, Udo De Haes J, de Kam ML, Franson KL, Cohen AF, van Gerven JM.

Br J Clin Pharmacol. 2013 Jun;75(6):1455-67. doi: 10.1111/bcp.12015.

9.

Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade.

Kleijn HJ, Zollinger DP, van den Heuvel MW, Kerbusch T.

Br J Clin Pharmacol. 2011 Sep;72(3):415-33. doi: 10.1111/j.1365-2125.2011.04000.x.

10.

Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers.

Zuurman L, Passier PC, de Kam ML, Kleijn HJ, Cohen AF, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1689-96. doi: 10.1177/0269881109106913. Epub 2009 Nov 25.

PMID:
19939872
11.

Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers.

Zuurman L, Passier PC, de Kam Ml, Kleijn HJ, Cohen AF, van Gerven JM.

J Psychopharmacol. 2009 Aug;23(6):633-44. doi: 10.1177/0269881108091551. Epub 2008 Jul 17.

PMID:
18635703
12.

Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects.

Ruwe FJ, Smulders RA, Kleijn HJ, Hartmans HL, Sitsen JM.

Hum Psychopharmacol. 2001 Aug;16(6):449-459.

PMID:
12404553

Supplemental Content

Loading ...
Support Center